BRIEF-EMA'S PRAC extends safety review of chronic Hep C treatments By: Reuters: Company News April 15, 2016 at 08:26 AM EDT * Started review of diabetes medicine canagliflozin after increase in amputations in ongoing trial Read More >> Related Stocks: AbbVie Bristol-Myers Squibb Gilead Sciences Johnson & Johnson